Table 2.
Drugs | Indication | Dose | Comment |
First line | |||
Methyldopa | PE with severe symptomsHypertension in pregnancy | 0.5–3 g/day PO in 2 divided doses | Established long term safety.Breast milk compatibleMild hypertensive effect and slow onset of action, hence may not be used alone |
Labetalol | PE with severe symptoms, usually IV formulation | Start with 20 mg IV bolusMayrequiredouble dose 10 min later | Rapid onset of actionStudies confirm safety in pregnancyMay cause maternal hepatotoxicity |
Hydralazine | PE with severe symptoms, usually IV formulation.Long-acting nifedipine | 5 mg IV slowly over 1 to 2 min30–90 mg once daily. May be increased at 7- to 14-day intervals, to maximum dose of 120 mg a day. | Usually breast milk compatible. More adverse effect than labetalolHypotensive effect is less predictable |
Nefidipine | PE with severe symptoms, immediate release oral formulation | Start with 10 mg POMay repeat dose 30 min later | Use particularly when IV access is not available.May cause rapid drops in BP. Concern of serious side effects when used simultaneous with magnesium sulfate. |
Second line | |||
Nicardipine | Resistant acute-onset severe hypertension when first line has failed | Give as IV infusion of 3 to 9 mg/hour | Delay onset of action (5–15 min). Titrate slowly to avoid overdose |
Sodium Nitroprusside | Acute life threatening hypertension associated with PE | Start with 0.24 µg/kg/min.May titrate to maximum dose of 5 µg/kg/min | Rarely used in dire emergency.Give for shortest amount of time to avoid toxicity (cyanide & thiocyanate) |
IV: intravenous; PE: preeclampsia; PO: per oral.